Table 2.
Summary of clinical studies and progress of neoadjuvant radiotherapy and chemotherapy for non-small cell lung cancer/esophageal cancer
| Disease type | Trail (or Name) | Phase | Stage (Or TNM) | Histologic Subtype | Neoadjuvant therapy | Number of Case | CT/RT | R0 Resection Rate | mPR/pCR | Survival |
|---|---|---|---|---|---|---|---|---|---|---|
| NSCLC | Pass HI [16] | II | IIIA (N2) | AC: 15/Other: 12 | CT (ACT) vs (ART) | 0.542361 | 4EP/54-60 Gy | None | None | mOS: 28.7 m vs 15.6 m |
| Rosell R [17] | III | IIIA (N2) | SCC: 42/AC: 14/Other: 4 | CT (ART) vs (ART) | 1.270833 | MIC/40 Gy | None | None | mOS: 26 m vs 8 m | |
| None | None | DFS: 20 m vs 5 m | ||||||||
| Roth JA [18] | -- | III | -- | CT vs NIL | 1.188889 | CEP | None | None | 5 year SR: 36% vs 15% | |
| Zhang CW [19] | -- | IIIA/IIIB | SCC: 226/AC: 175/ASC: 6 | cCRT vs RT vs CT | 86:114:207 | NP/40 Gy | 91.6/84.1/81.2 | None | 3 year SR: 72.6% vs 63.2% vs 64.1% | |
| MIKOS P [20] | III | IIIA/N2 | SCC: 78/AC: 100/Other: 53 | CRT vs CT | 117:115 | DC/44 Gy | None | None | EFS: 12.8 m vs 11.6 m | |
| None | None | mOS: 37.1 m vs 26.2 m | ||||||||
| EC | CROSS [31] | -- | T1N1/T2-3N0-1 | SCC: 84/AC: 275 | CRT vs NIL | 178:188 | TC/41.4 Gy | 92/69 | None | OS: 49.4 m vs 24 m |
| NEOCRTEC5010 [32] | III | T1-4N1M0/T4N0M0 | SCC | cCRT vs NIL | 224:227 | NP/40 Gy | 98.4/91.2 | pCR: 43.2% vs NIL | mOS: 101 m vs 66.5 m | |
| DFS: 100.1 m vs 41.7 m | ||||||||||
| JCOG9907 [34] | III | II/III (Excluding T4) | SCC | CT vs (ACT) | 164:166 | CF | None | None | 5 year SR: 55% vs 43% | |
| JCOG1109 [36] | III | IB/II/III (Excluding T4) | SCC | CT vs CT vs CRT | 199:202:200 | CF vs DCF vs CF | 90.3:94.5:98.9 | pCR: 2.1 vs 19.8 vs 38.5 | mOS: 5.6 y vs NR vs 7.0 y | |
| PFS: 2.7 y vs NR vs 5.3 y | ||||||||||
| Cuunningham D [38] | III | -- | AC | CT (ACT) vs NIL | 250:253 | ECF | None | None | 5 year SR: 36% vs 23% | |
| Zhang G [39] | -- | T1N+M0/T2-4aN0-3M0 | SCC | CRT vs CT | 194:133 | CF or TC/32.4-50 Gy | 99.5:99.2 | pCR: 35.1 vs 6.0 | mOS: 96 m vs 88 m | |
| 5 year SR: 59.5% vs 59.6% |
Note: CT: Chemotherapy; RT: Radiotherapy; mPR: Major pathologic response; pCR: pathologic complete response; AC: Adenocarcinoma; SCC: Squamous cell carcinoma; ASC: Adenosquamous carcinoma; ACT: Adjuvant chemotherapy; ART: Adjuvant radiotherapy; CRT: Chemoradiotherapy; cCRT: Concurrent chemoradiotherapy; EP: Etoposide and cisplatin; MIC: Mitomycin and ifosfamide and cisplatin; CEP: Cyclophosphamide and etoposide and cisplatin; VC: Vinorelbine and cisplatin; DC: Docetaxel and cisplatin; TC: Paclitaxel and carboplatin; CF: Fluorouracil and platinum; DCF: Docetaxel and fluorouracil and platinum; ECF: Epirubicin and fluorouracil and cisplatin; mOS: Median overall survival; DFS: Disease-free survival; SR: Survival rate; EFS: Event-free survival; m: month; y: year; NR: Not reached; --: Not mentioned.